Keep fit and trim in midlife to age well – how diet that avoids weight gain pays dividends
Advertisement
The type and quality of carbohydrates a person consumes in their forties and fifties is likely to be a determining factor in how healthily they age, research shows.
'Sustained weight loss from overweight to healthy weight in midlife was associated with decreased risk of chronic diseases,' according to a team of doctors and scientists at the University of Helsinki and the University of Turku in Finland, and University College London in the United Kingdom.
Achieving this weight loss without having surgery or taking drugs means 'long-term health benefits beyond its associations with decreased
diabetes risk ', said the researchers, whose study covering around 23,100 people was published by the American Medical Association (AMA).
Keeping trim in your forties and fifties, including by eating well, reduces the risk of developing chronic conditions such as diabetes, according to doctors and scientists from Finland and the UK. Photo: Shutterstock
The AMA also recently published a study of around 47,000 women carried out by a team from Tufts University and Harvard University, both in the US state of Massachusetts, in which the researchers say
fibre and carbohydrates are 'favourably linked to
healthy ageing and other positive health outcomes in older women.'
Advertisement
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
10 hours ago
- South China Morning Post
Healthy babies born in UK using pioneering 3-person IVF technique
The results of the much-awaited UK trial were published in several papers in the New England Journal of Medicine. Some have called the result of this process 'three-parent babies', though researchers have pushed back at this term because only roughly 0.1 per cent of the newborn's DNA comes from the donor. In 2015, Britain became the first country to approve an in vitro fertilisation (IVF) technique that uses a small amount of healthy mitochondrial DNA from the egg of a donor - along with the mother's egg and father's sperm. One out of every 5,000 births is affected by mitochondrial diseases, which cannot be treated, and include symptoms such as impaired vision, diabetes and muscle wasting. The findings were hailed as a breakthrough which raises hopes that women with mutations in their mitochondrial DNA could one day have children without passing debilitating or deadly diseases on to the children. Eight healthy babies have been born in the UK using a new IVF technique that successfully reduced their risk of inheriting genetic diseases from their mothers, the results of a world-first trial said Wednesday. One out of every 5,000 births is affected by mitochondrial diseases, which cannot be treated. File photo: Shutterstock Out of 22 women to undergo the treatment at the Newcastle Fertility Centre in northeast England, eight babies were born. The four boys and four girls now range from under six months to over two years old. The amount of mutated mitochondrial DNA – which causes disease – was reduced by 95-100 per cent in six of the babies, according to the research. For the other two newborns, the amount fell by 77–88 per cent, which is below the range that causes disease. This indicates the technique was 'effective in reducing transmission' of diseases between mother and child, one of the studies said. The eight children are currently healthy, though one had a disturbance of their heart's rhythm which was successfully treated, the researchers said. Their health will be followed up over the coming years to see if problems arise. Nils-Goran Larsson, a Swedish reproductive expert not involved in the research, hailed the 'breakthrough'. The new technique offers a 'very important reproductive option' for families affected by 'devastating' mitochondrial diseases, he added. Mitochondrial donation remains controversial and has not been approved in many countries, including the United States and France. Religious leaders have opposed the procedure because it involves the destruction of human embryos. Other opponents have expressed fears it could pave the way for genetically engineered 'designer babies'. An ethical review carried out by the UK's independent Nuffield Council on Bioethics was 'instrumental' in conducting the new research, the council's director Danielle Hamm said Wednesday. Peter Thompson, head of the UK's Human Fertilisation and Embryology Authority which approved the procedure, said only people with a 'very high risk' of passing on a mitochondrial disease would be eligible for the treatment. Ethical concerns have also been raised over the use of mitochondrial donation for infertility in Greece and Ukraine. French mitochondrial disease specialist Julie Stefann said that 'it is a question of the risk-benefit ratio: for a mitochondrial disease, the benefit is obvious'. 'In the context of infertility, it has not been proven,' she added. Oxford University reproductive genetics expert Dagan Wells observed that 'some scientists will be a little disappointed that so much time and effort has, so far, only led to the birth of eight children'. Among the children being closely monitored are three that showed some signs of what is known as 'reversal', which is still little understood. It is 'a phenomenon where the therapy initially succeeds in producing an embryo with very few defective mitochondria, but by the time the child is born the proportion of abnormal mitochondria in its cells has significantly increased,' he explained. Advertisement
South China Morning Post
2 days ago
- South China Morning Post
‘China's Ozempic' pioneer inks deal with JD Health for online distribution
China's weight loss drugs market could grow to US$5.6 billion by 2035, according to Goldman Sachs Innovent Biologics, the first Chinese company to win regulatory approval to sell a GLP-1 drug for weight loss and diabetes, will leverage JD Health's online distribution network as it seeks to grab a slice of a market that could be worth 40 billion yuan (US$5.6 billion) in a decade. The companies will collaborate on supply chain and sales channel development ahead of Innovent's launch of mazdutide, as well as engage in a consumer education campaign. 'Innovent and JD Health will join hands to popularise knowledge about weight loss and blood sugar control via on and offline channels,' Innovent said in a statement posted on its WeChat account on Tuesday. Late last month, eastern Jiangsu province-based Innovent said it received Chinese regulatory approval for mazdutide, which it claimed was the world's first to mimic the natural hormones of GLP-1 and glucagon, with the latter playing a crucial role in regulating blood glucose levels. GLP-1 drugs mimic the actions of the naturally produced hormone glucagon-like peptide-1, which regulates blood sugar levels, suppresses appetite and slows digestion. A woman injects insulin with an insulin pen to treat her diabetes at home. Photo: Shutterstock Images 'Innovent will make its breakthrough dual-target, liver fat-reducing weight loss therapy available to obese patients as soon as possible, to contribute towards the weight management and healthy China initiatives,' said chairman Michael Yu Dechao, without giving a time frame. Some 34.3 per cent of mainland Chinese adults were estimated to be overweight and 11.2 per cent were obese, according to a 2022 study involving nearly 63,000 participants in 10 provinces. The results were published in 2024 by Public Health, a peer-reviewed journal. Newsletter Every Saturday SCMP Global Impact By submitting, you consent to receiving marketing emails from SCMP. If you don't want these, tick here {{message}} Thanks for signing up for our newsletter! Please check your email to confirm your subscription. Follow us on Facebook to get our latest news. Over 70 per cent of the population would be overweight or obese by 2030, and if the problem was not addressed effectively, it would consume 22 per cent of the nation's total healthcare budget, according to the National Health Commission. Last April, Beijing launched a nationwide weight management campaign as part of its 'healthy China' 2019-2030 action plan, saying obesity had become 'a major public health threat'. China's weight loss drugs market could grow to 40 billion yuan in 2035, according to Chen Ziyi, Goldman Sachs' head of Asia healthcare research. Currently, sales are primarily driven by Denmark-based Novo Nordisk, which reported US$285 million in GLP-1 drug sales for diabetes in China in the first quarter, and US$11 million in sales for weight loss applications. Dozens of Chinese firms are conducting clinical trials on both generic and novel alternatives. Globally, industry estimates for sales of anti-obesity drugs range from US$100 billion to US$150 billion by 2035. JD Health's cold storage facilities in some 300 cities across the mainland could meet Innovent's requirement for GLP-1 drugs to be stored at 2 to 8 degrees Celsius when in transit, Innovent said. Innovent, among the first batch of biotech firms that went public in Hong Kong in 2018, has since launched 16 novel drugs for various types of cancer, as well as for autoimmune, metabolic and eye diseases. Beijing-based JD Health operates one of China's largest online healthcare platforms, with 183.6 million annual active users and an average daily online medical consultation volume of 490,000 last year. Its distribution network spans over 100,000 third-party merchants. Last year, JD Health helped multiple global pharmaceutical firms distribute new drugs in China, including US-based Eli Lilly's GLP-1 diabetes and weight loss drug tirzepatide, a rival to Novo Nordisk's semaglutide. Semaglutide is formulated and marketed as Ozempic for diabetes and Wegovy for weight loss.
South China Morning Post
2 days ago
- South China Morning Post
‘China's Ozempic' pioneer inks deal with JD Health for online distribution
Innovent Biologics, the first Chinese company to win regulatory approval to sell a GLP-1 drug for weight loss and diabetes, will leverage JD Health's online distribution network as it seeks to grab a slice of a market that could be worth 40 billion yuan (US$5.6 billion) in a decade. The companies will collaborate on supply chain and sales channel development ahead of Innovent's launch of mazdutide, as well as engage in a consumer education campaign. 'Innovent and JD Health will join hands to popularise knowledge about weight loss and blood sugar control via on and offline channels,' Innovent said in a statement posted on its WeChat account on Tuesday. Late last month, eastern Jiangsu province-based Innovent said it received Chinese regulatory approval for mazdutide, which it claimed was the world's first to mimic the natural hormones of GLP-1 and glucagon, with the latter playing a crucial role in regulating blood glucose levels. GLP-1 drugs mimic the actions of the naturally produced hormone glucagon-like peptide-1, which regulates blood sugar levels, suppresses appetite and slows digestion. A woman injects insulin with an insulin pen to treat her diabetes at home. Photo: Shutterstock Images 'Innovent will make its breakthrough dual-target, liver fat-reducing weight loss therapy available to obese patients as soon as possible, to contribute towards the weight management and healthy China initiatives,' said chairman Michael Yu Dechao, without giving a time frame.
